Then, we performed IHC staining analysis for CD68 and CCL2 in an in-house cohort, and the results showed that high BCL2A1 expression was significantly associated with CD68 and CCL2 expression in gliomas (Figure 9B, 9C). This evidence concerns the gene BCL2A1 and central nervous system cancer.